Log in

NYSE:BMY - Bristol-Myers Squibb Stock Price, Forecast & News

$66.38
+0.30 (+0.45 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$65.98
Now: $66.38
$66.83
50-Day Range
$62.78
MA: $65.01
$67.43
52-Week Range
$42.48
Now: $66.38
$68.34
Volume7.53 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio30.31
Dividend YieldN/A
BetaN/A
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
CUSIP11012210
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees23,300
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.


Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb declared a quarterly dividend on Thursday, December 5th. Shareholders of record on Friday, January 3rd will be given a dividend of $0.45 per share on Monday, February 3rd. This represents a $1.80 dividend on an annualized basis and a yield of 2.71%. The ex-dividend date of this dividend is Thursday, January 2nd. This is a boost from Bristol-Myers Squibb's previous quarterly dividend of $0.41. View Bristol-Myers Squibb's Dividend History.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb Co (NYSE:BMY) issued its earnings results on Thursday, February, 6th. The biopharmaceutical company reported $1.22 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.88 by $0.34. The biopharmaceutical company earned $7.95 billion during the quarter, compared to analyst estimates of $6.20 billion. The firm's revenue for the quarter was up 33.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.94 earnings per share. View Bristol-Myers Squibb's Earnings History.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for Bristol-Myers Squibb.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb updated its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share guidance of $6.00-$6.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.20. The company issued revenue guidance of $40.5-$42.50 billion, compared to the consensus revenue estimate of $42.21 billion.

What price target have analysts set for BMY?

14 brokerages have issued 12-month price objectives for Bristol-Myers Squibb's stock. Their forecasts range from $53.00 to $80.00. On average, they anticipate Bristol-Myers Squibb's share price to reach $62.64 in the next year. This suggests that the stock has a possible downside of 5.6%. View Analyst Price Targets for Bristol-Myers Squibb.

What is the consensus analysts' recommendation for Bristol-Myers Squibb?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bristol-Myers Squibb.

Has Bristol-Myers Squibb been receiving favorable news coverage?

News headlines about BMY stock have been trending extremely negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bristol-Myers Squibb earned a news impact score of -5.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Bristol-Myers Squibb.

Who are some of Bristol-Myers Squibb's key competitors?

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Chicago Bridge & Iron (CBI), Pfizer (PFE), Diebold Nixdorf (DBD), Verizon Communications (VZ), Bank of America (BAC), Intel (INTC), NVIDIA (NVDA) and Walt Disney (DIS).

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the folowing people:
  • Dr. Giovanni Caforio, Chairman & CEO (Age 54)
  • Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 59)
  • Dr. Thomas J. Lynch Jr., Exec. VP & Chief Scientific Officer (Age 58)
  • Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 58)
  • Mr. Paul von Autenried, Sr. VP & Chief Information Officer (Age 57)

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by many different of retail and institutional investors. Top institutional investors include Charles Schwab Investment Management Inc. (1.21%), Loomis Sayles & Co. L P (0.84%), Sumitomo Mitsui Trust Holdings Inc. (0.65%), Franklin Resources Inc. (0.61%), TIG Advisors LLC (0.57%) and California Public Employees Retirement System (0.48%). Company insiders that own Bristol-Myers Squibb stock include Dinesh C Paliwal, John E Elicker, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini and Theodore R Samuels II. View Institutional Ownership Trends for Bristol-Myers Squibb.

Which institutional investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including Baupost Group LLC MA, Franklin Resources Inc., MUFG Securities EMEA plc, Jacobs Levy Equity Management Inc., Barrow Hanley Mewhinney & Strauss LLC, Loomis Sayles & Co. L P, PGGM Investments and Nikko Asset Management Americas Inc.. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include John E Elicker, Karen Murphy Santiago and Louis S Schmukler. View Insider Buying and Selling for Bristol-Myers Squibb.

Which institutional investors are buying Bristol-Myers Squibb stock?

BMY stock was acquired by a variety of institutional investors in the last quarter, including TIG Advisors LLC, Charles Schwab Investment Management Inc., Prudential Financial Inc., Sumitomo Mitsui Trust Holdings Inc., Senator Investment Group LP, Swiss National Bank, California Public Employees Retirement System and New York State Common Retirement Fund. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Dinesh C Paliwal, Robert J Bertolini and Theodore R Samuels II. View Insider Buying and Selling for Bristol-Myers Squibb.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $66.38.


MarketBeat Community Rating for Bristol-Myers Squibb (NYSE BMY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  990 (Vote Outperform)
Underperform Votes:  899 (Vote Underperform)
Total Votes:  1,889
MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote "Outperform" if you believe BMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel